0001801170-25-000275
SEC filingMembership growth drove 39% revenue increase; medical costs rose 51%, pressuring margins; Adjusted EBITDA fell 28%.
For the nine months ended September 30, 2025, Clover Health reported total revenues of $1.44B, up 38.9% from $1.03B in the prior-year period, driven by a 32% increase in average Medicare Advantage members. Premiums earned net grew 38.6% to $1.41B. However, net medical claims incurred surged 51.3% to $1.15B, far outpacing revenue growth due to higher Part D cost sharing from the Inflation Reduction Act and less favorable prior-period development compared to 2024. This led to a net loss from continuing operations of $36.2M, compared to a loss of $24.8M a year ago. Operating margin worsened to -2.5% from -2.3%, a decline of 17 bps.
Clover operates one reportable segment: Insurance. The Insurance segment generated $1.41B in net premiums earned, with member growth as the primary volume driver. Gross medical claims incurred rose 55% to $1.19B, reflecting increased utilization and cost trends. Adjusted SG&A improved as a percentage of revenue from 20.2% to 16.5%, indicating operating leverage from scale. However, the benefits expense ratio (BER) increased to 89.4% gross (from 80.6%), and normalized BER (excluding prior-period development) was 88.9% versus 84.9%, highlighting persistent margin headwinds.
Management did not provide specific financial guidance for upcoming periods. Key forward-looking factors include the CMS star ratings update: PPO plans dropped to 3.5 stars for 2026 (impacting 2027 payments), while HMO plans improved to 4.0 stars. With over 97% of members in PPO plans, the star downgrade could pressure future revenue from quality bonuses. The company expects cash, equivalents, and investments of $395.9M to cover near-term obligations, but noted potential need for future financing. Operational focus remains on member retention, cost management, and scaling the Clover Assistant platform to improve clinical outcomes and lower claim costs.
As of September 30, 2025, Clover Health held $190.1 million in cash and cash equivalents, down slightly from $194.5 million at December 31, 2024. Total investment securities (available-for-sale and held-to-maturity) amounted to $205.9 million (fair value), compared to $243.1 million at year-end 2024. Total assets were $559.7 million, while total liabilities stood at $218.7 million, resulting in stockholders' equity of $340.9 million. The company's insurance subsidiaries are subject to dividend restrictions, with no dividends paid or authorized during the period.
The filing does not disclose any material purchase commitments or contractual obligations beyond those arising in the ordinary course of business. The company has no debt outstanding. Commitments and contingencies are limited to legal matters, including the previously settled securities class action, which was funded by insurance proceeds.
During the nine months ended September 30, 2025, Clover Health repurchased 5,069,423 shares of common stock for $18.3 million. The company paid $27.7 million in cash for shares withheld related to stock-based compensation. Capital expenditures were $1.4 million. No dividends were declared or paid. The company has no debt, and no new debt was issued or repaid during the period.
Clover Health operates as a single reportable segment: Insurance. The Insurance segment provides PPO and HMO plans to Medicare Advantage members. For the nine months ended September 30, 2025, the segment generated $1.41 billion in net premiums earned and reported a segment net loss of $95.0 million. The CODM uses net income to assess performance and allocate resources. No geographic breakdown is provided.
Net loss widened to $(36.2) million from $(20.9) million, yet operating cash flow remained positive at $1.2 million, supported by $78.7 million in stock-based compensation. However, the dramatic decline from $120.7 million in the prior period reflects significant working capital headwinds: healthcare receivables consumed $6.4 million (vs. a $26.9 million source last year), unpaid claims decreased by $15.9 million (vs. a $30.3 million increase), and accrued salaries swung from a $14.4 million source to a $1.9 million use. Capex intensity remained low at $1.4 million, representing about 1.2x reported depreciation. Free cash flow (CFO minus capex) was negative $(0.2) million, insufficient to cover $18.3 million in share repurchases and $27.7 million in tax withholding payments on equity awards. The company relied on investing activities (net $39.1 million from securities sales/maturities) to fund financing outflows. Overall, cash generation weakened materially due to adverse working capital changes, though the core business still produced positive CFO from operations.